https://www.scmp.com/rss/523765/feed The latest news and top stories on Eli Lilly. An Indianapolis, Indiana-based entity in the pharmaceutical sector, Eli Lilly specialises in discovering, developing and manufacturing prescription drugs. It primarily serves healthcare providers and patients worldwide and is known for its pioneering work in insulin and the polio vaccine. en https://assets.i-scmp.com/static/img/icons/scmp-meta-1200x630.png https://www.scmp.com Reuters Reuters Soon-to-be brides and grooms seeking ⁠short cuts to shed pounds before the big day have become the latest consumer target ⁠for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a “Mounjaro bride” package, while other clinics have woven weight-loss injections into “pre-wedding” transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers “guided nutrition, Mounjaro and smart workouts” to prepare brides... https://www.scmp.com/news/asia/south-asia/article/3349011/here-comes-mounjaro-bride-indian-women-turn-weight-loss-drug-wedding?utm_source=rss_feed https://www.scmp.com/news/asia/south-asia/article/3349011/here-comes-mounjaro-bride-indian-women-turn-weight-loss-drug-wedding?utm_source=rss_feed Sat, 04 Apr 2026 02:25:11 +0000 Julie Zhang Julie Zhang Insilico Medicine has signed a potential multibillion-dollar deal with Eli Lilly to license out an early-stage drug pipeline and provide its artificial intelligence platform services in research and development collaborations. Under the agreement announced on Monday, US-headquartered, Hong Kong-listed Insilico will receive an upfront payment of US$115 million. The deal could have a total value of around US$2.75 billion tied to development, regulatory and commercial milestones, plus tiered... https://www.scmp.com/business/china-business/article/3348333/hong-kong-listed-insilico-medicine-signs-ai-drug-development-deal-eli-lilly?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3348333/hong-kong-listed-insilico-medicine-signs-ai-drug-development-deal-eli-lilly?utm_source=rss_feed Mon, 30 Mar 2026 01:24:48 +0000 Daniel Ren Daniel Ren The cross-border outlicensing activities of Chinese biotech firms reached a record transaction value of US$60 billion in the first quarter of 2026, driven by multinational pharmaceutical companies’ growing appetite for the country’s promising drug candidates. The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA)... https://www.scmp.com/business/china-business/article/3348295/china-biotech-deals-hit-record-innovative-drugs-draw-interest-multinationals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3348295/china-biotech-deals-hit-record-innovative-drugs-draw-interest-multinationals?utm_source=rss_feed Sun, 29 Mar 2026 11:26:21 +0000 Mia Nurmamat,Xinyi Wu Mia Nurmamat,Xinyi Wu Germany’s chemical giant BASF has launched operations at its China production base – its largest overseas investment to date – with a total outlay of €8.7 billion (US$10 billion), and the country’s first wholly foreign-owned large-scale Verbund site. The company on Thursday inaugurated the world-scale complex in Zhanjiang, Guangdong province, designed to run entirely on renewable electricity. A Verbund site is an integrated chemical complex where plants, energy use and materials are... https://www.scmp.com/business/article/3348021/basf-launches-biggest-overseas-project-china-green-powered-mega-site?utm_source=rss_feed https://www.scmp.com/business/article/3348021/basf-launches-biggest-overseas-project-china-green-powered-mega-site?utm_source=rss_feed Thu, 26 Mar 2026 14:00:12 +0000 Julie Zhang Julie Zhang At least 10 weight-loss injections and oral pills are lining up for regulatory approval in China, in a market projected to reach about US$14 billion by 2030. Novo Nordisk’s blockbuster semaglutide, which generated about US$35 billion in global revenue last year, lost patent protection in China on March 20, clearing the way for rivals. The rush comes as China’s drug regulator accelerates approvals of innovative therapies, helped by a surge in out-licensing deals with global pharmaceutical... https://www.scmp.com/business/china-business/article/3347869/chinas-weight-loss-drug-makers-take-global-giants-novo-nordisk-patent-expires?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3347869/chinas-weight-loss-drug-makers-take-global-giants-novo-nordisk-patent-expires?utm_source=rss_feed Thu, 26 Mar 2026 03:00:08 +0000 Julie Zhang Julie Zhang AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a group of foreign players building new plants in China amid geopolitical tensions. The moves are part of a US$15 billion commitment the British firm pledged to make in the world’s second-largest drug market through 2030, unveiled during UK Prime Minister Keir Starmer’s visit to Beijing in January. China’s manufacturing capabilities, integrated... https://www.scmp.com/business/china-business/article/3347266/global-drug-giants-double-down-china-amid-trend-build-self-reliant-supply-chains?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3347266/global-drug-giants-double-down-china-amid-trend-build-self-reliant-supply-chains?utm_source=rss_feed Fri, 20 Mar 2026 06:30:09 +0000 Julie Zhang Julie Zhang Chinese contract drug makers – including WuXi AppTec, WuXi Biologics and WuXi XDC – face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house and reconfigure supply chains amid rising US-China tensions. While near-term earnings remained largely locked in, visibility beyond that was limited, according to Cui Cui, head of healthcare research for Asia at Jefferies. “Earnings visibility for 2026 and 2027 is still very strong – revenue momentum is largely... https://www.scmp.com/business/china-business/article/3346911/us-reshoring-drive-casts-shadow-over-chinas-contract-drug-makers-analyst?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3346911/us-reshoring-drive-casts-shadow-over-chinas-contract-drug-makers-analyst?utm_source=rss_feed Tue, 17 Mar 2026 11:48:41 +0000 Themis Qi,Julie Zhang Themis Qi,Julie Zhang Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical giants in the world’s second-largest healthcare market. The move would bring the total cumulative investment of Eli Lilly, the world’s largest pharmaceutical company by market capitalisation, in China to nearly US$6 billion, according to a statement released on its WeChat account on... https://www.scmp.com/business/banking-finance/article/3346260/eli-lilly-boosts-china-footprint-us3-billion-plan-expand-supply-chain?utm_source=rss_feed https://www.scmp.com/business/banking-finance/article/3346260/eli-lilly-boosts-china-footprint-us3-billion-plan-expand-supply-chain?utm_source=rss_feed Wed, 11 Mar 2026 13:39:53 +0000 Edith Lin Edith Lin Hong Kong authorities have arrested a 30-year-old woman on suspicion of illegally selling poisons and unregistered pharmaceutical products, after an undercover operation found her offering weight-loss injections online. The Department of Health said on Wednesday that it acted on a tip-off and obtained the anti-obesity medicine through a transaction on an instant messaging app. The product bore a Japanese label and indicated that it contained tirzepatide. According to a photo released by the... https://www.scmp.com/news/hong-kong/health-environment/article/3345475/hong-kong-woman-30-arrested-over-illegal-sale-slimming-injection?utm_source=rss_feed https://www.scmp.com/news/hong-kong/health-environment/article/3345475/hong-kong-woman-30-arrested-over-illegal-sale-slimming-injection?utm_source=rss_feed Wed, 04 Mar 2026 15:17:12 +0000 Julie Zhang Julie Zhang The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion. The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said. The latest deals, Sino Biopharmaceutical’s agreement with... https://www.scmp.com/business/china-business/article/3345404/china-outlicensing-tops-us52-billion-first-two-months-rise-global-deals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3345404/china-outlicensing-tops-us52-billion-first-two-months-rise-global-deals?utm_source=rss_feed Wed, 04 Mar 2026 09:30:11 +0000 Julie Zhang Julie Zhang Hong Kong-listed mainland Chinese pharmaceutical companies are on track to deliver full-year profits, as surging drug sales and lucrative out-licensing deals with global partners start to pay off after years of research and development outlay. “Despite domestic challenges, particularly drug pricing pressure, the earnings performance of innovative drugs should still fare well in China in 2025,” said Tony Ren, head of Asia Healthcare Research at Macquarie Capital. Innovent Biologics, the first... https://www.scmp.com/business/china-business/article/3344928/hong-kong-listed-chinese-drug-firms-set-turn-corner-rising-sales-licensing-deals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3344928/hong-kong-listed-chinese-drug-firms-set-turn-corner-rising-sales-licensing-deals?utm_source=rss_feed Sun, 01 Mar 2026 04:00:22 +0000 Aileen Chuang Aileen Chuang China’s Harbour BioMed has struck a deal worth more than US$1.2 billion with a clinical-stage biotechnology company to develop and commercialise an antibody outside China, as the country’s novel drug makers increasingly secure not only upfront licensing fees but also long-term international partnerships. The Shanghai-based company announced a licence and equity agreement on Monday with Solstice Oncology, a firm established by a syndicate of venture capital investors, for the exclusive... https://www.scmp.com/business/china-business/article/3344311/wave-chinese-biotech-deals-builds-harbour-biomed-solstice-sign-us12-billion-pact?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3344311/wave-chinese-biotech-deals-builds-harbour-biomed-solstice-sign-us12-billion-pact?utm_source=rss_feed Mon, 23 Feb 2026 07:15:13 +0000 Julie Zhang Julie Zhang Investors in mainland China raised their stakes in Hong Kong-listed drug makers through the cross-border trading link over the past week, as a wave of out-licensing deals between the country’s pharmaceutical firms and global partners rolls on. The Hang Seng Southbound Connect Hong Kong Innovative Drug Index, which tracks around 40 of the largest Hong Kong-listed Chinese drug manufacturers, biotech researchers and AI-driven drug developers by market capitalisation, rose about 8 per cent between... https://www.scmp.com/business/banking-finance/article/3343011/chinese-investors-pour-hong-kong-listed-drug-stocks-international-deals-multiply?utm_source=rss_feed https://www.scmp.com/business/banking-finance/article/3343011/chinese-investors-pour-hong-kong-listed-drug-stocks-international-deals-multiply?utm_source=rss_feed Tue, 10 Feb 2026 05:00:18 +0000 Julie Zhang Julie Zhang Mainland China could become one of the first markets in the world to approve a drug fully designed by artificial intelligence, as advances in AI and human genetics combine to create a “seismic shift” in drug development, according to executives of pharmaceutical giants. “We will see in 2026 that we move from AI-assisted discovery to fully AI-designed compounds, perhaps entering the pipeline,” said Marc Horn, president of Merck China, at the Asian Financial Forum on Tuesday in Hong Kong. “We... https://www.scmp.com/business/china-business/article/3341432/china-could-approve-first-fully-ai-designed-drug-next-year-merck-executive-says?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3341432/china-could-approve-first-fully-ai-designed-drug-next-year-merck-executive-says?utm_source=rss_feed Tue, 27 Jan 2026 12:00:10 +0000 Fiona Sun Fiona Sun Weight-loss injections have fallen under the spotlight in Hong Kong after the Post discovered over-the-counter sellers operating locally, and a recent study found that nearly one in two residents was overweight or obese. The Post’s investigation found the prescription-only medicines were available for purchase on some online platforms and at a pharmacy without the need for a doctor’s approval, sparking concerns about potential health risks. The Post looks into the matter and examines the... https://www.scmp.com/news/hong-kong/health-environment/article/3341137/worth-weight-what-hongkongers-should-know-about-slimming-injections?utm_source=rss_feed https://www.scmp.com/news/hong-kong/health-environment/article/3341137/worth-weight-what-hongkongers-should-know-about-slimming-injections?utm_source=rss_feed Sun, 25 Jan 2026 02:30:20 +0000 SCMP Reporters SCMP Reporters Online retailers and a Hong Kong pharmacy are offering slimming injections without prescriptions despite local authorities requiring a doctor’s approval before purchase, a Post investigation has found, with an expert warning it could lead to misuse. Weight-loss injections, which have been approved by Hong Kong authorities for use, have become increasingly popular around the world and work by targeting hormones, reducing appetite and slowing down food digestion. In Hong Kong, such products are... https://www.scmp.com/news/hong-kong/health-environment/article/3341117/no-prescription-no-problem-hong-kongs-grey-zone-weight-loss-injections?utm_source=rss_feed https://www.scmp.com/news/hong-kong/health-environment/article/3341117/no-prescription-no-problem-hong-kongs-grey-zone-weight-loss-injections?utm_source=rss_feed Sat, 24 Jan 2026 13:08:58 +0000 Reuters Reuters Many patients using highly effective GLP-1 drugs may not regain lost weight quickly when they stop treatment, ‌according to an analysis of real-world data that sheds light on a chief concern about the therapies. Among thousands of patients treated at a ‍large network of academic medical clinics in the United States, most had kept the weight off or lost even more 18 months after stopping semaglutide, sold by Novo Nordisk as Ozempic and Wegovy, or tirzepatide, sold by Eli Lilly as Mounjaro and... https://www.scmp.com/lifestyle/health-wellness/article/3340941/stopping-glp-1-drugs-ozempic-often-does-not-mean-weight-regain-us-research-suggests?utm_source=rss_feed https://www.scmp.com/lifestyle/health-wellness/article/3340941/stopping-glp-1-drugs-ozempic-often-does-not-mean-weight-regain-us-research-suggests?utm_source=rss_feed Fri, 23 Jan 2026 13:15:07 +0000 Julie Zhang Julie Zhang China has emerged as a credible challenger to the US in artificial intelligence-driven drug discovery, where advantage depends not only on computing prowess but also on the ability to effectively mine data, from genomes to clinical trial results, according to Leung Chuen-yan, a private equity investor and life sciences scientist. “Globally, the way companies develop and use AI to discover drugs is similar, from finding the drug target and designing the molecule to planning clinical trials,” said... https://www.scmp.com/business/china-business/article/3340403/china-challenges-us-ai-drug-race-rivals-still-reliant-each-other?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3340403/china-challenges-us-ai-drug-race-rivals-still-reliant-each-other?utm_source=rss_feed Tue, 20 Jan 2026 00:30:11 +0000 Julie Zhang Julie Zhang A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease, which affects some 55 million people worldwide and could cost the global economy US$2.8 trillion by 2030. The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro’s antibody candidates to develop drugs for the progressive brain disease. SciNeuro’s novel amyloid beta targeted... https://www.scmp.com/business/china-business/article/3339691/chinas-scineuro-novartis-sign-us17-billion-licensing-deal-develop-alzheimers-drugs?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3339691/chinas-scineuro-novartis-sign-us17-billion-licensing-deal-develop-alzheimers-drugs?utm_source=rss_feed Tue, 13 Jan 2026 05:11:08 +0000 Julie Zhang Julie Zhang Foreign and mainland Chinese drug makers are fighting for a multibillion-dollar slice of the domestic weight-loss market by slashing prices by as much as 80 per cent, as China faces a worsening obesity crisis. Competition in the sector, dominated by global pharmaceutical giants Novo Nordisk and Eli Lilly, intensified after both secured obesity-drug approvals in China in 2024. The landscape is set to shift further when the patent on Novo Nordisk’s semaglutide expires in March in China, opening... https://www.scmp.com/business/china-business/article/3339544/chinas-weight-loss-drug-war-prices-slashed-80-obesity-crisis-worsens?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3339544/chinas-weight-loss-drug-war-prices-slashed-80-obesity-crisis-worsens?utm_source=rss_feed Mon, 12 Jan 2026 23:30:09 +0000 Julie Zhang Julie Zhang Irina Zhou’s five-year-old cat has gained about a kilogram every year for the past three years. She knows the extra weight puts her pet at risk of obesity-related diseases and could even shorten his life. “My parents just can’t bear to see the cat go hungry,” the 29-year-old Zhou said. “If the weight starts to affect his health, I might consider trying weight-loss medicines for him.” The idea of using obesity drugs for pets drew public attention after Fosun Pharma’s unit Yao Pharma signed a... https://www.scmp.com/business/china-business/article/3338820/meow-or-never-chinas-pudgy-pets-spark-race-weight-loss-drugs?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3338820/meow-or-never-chinas-pudgy-pets-spark-race-weight-loss-drugs?utm_source=rss_feed Wed, 07 Jan 2026 00:30:10 +0000 Julie Zhang Julie Zhang Biotech firm Insilico Medicine, backed by the Hong Kong Investment Corporation (HKIC), is building a “digital Einstein” to revolutionise how scientists discover new medicines, and plans to continue expanding its research base in China to stay ahead of global rivals after its Hong Kong listing on Tuesday. “Biotechnology is a high-risk field like a ‘molecular casino’,” said founder Alex Zhavoronkov. “Even with artificial intelligence, you can lose 90 per cent of the time.” The 11-year-old company... https://www.scmp.com/business/china-business/article/3337942/china-vital-insilicos-plan-build-biotechs-ai-einstein-drug-discovery?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3337942/china-vital-insilicos-plan-build-biotechs-ai-einstein-drug-discovery?utm_source=rss_feed Tue, 30 Dec 2025 02:13:46 +0000 Aileen Chuang Aileen Chuang Six companies debuted on the Hong Kong stock exchange on Tuesday, capping a year that reaffirmed the city’s dominance as the world’s top initial public offering (IPO) market and one of the best-performing benchmarks. The six debutants raised a combined HK$6.99 billion (US$899 million), adding to several sizeable deals this year. As of Tuesday, the Hong Kong IPO market raised HK$285.8 billion from 119 listings, with first-day trading showing an average share price gain of nearly 40 per cent,... https://www.scmp.com/business/banking-finance/article/3338086/insilico-medicine-leads-sextet-hong-kong-ipos-capping-banner-year-fundraising?utm_source=rss_feed https://www.scmp.com/business/banking-finance/article/3338086/insilico-medicine-leads-sextet-hong-kong-ipos-capping-banner-year-fundraising?utm_source=rss_feed Tue, 30 Dec 2025 01:40:43 +0000 Reuters Reuters Global pharmaceutical giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India’s booming obesity drug market before cheaper generic versions hit shelves ‌in March next year. Novo’s strategy emphasises price cuts and accelerated launches, while Lilly’s products benefited from hitting the market early. Both companies focused on aggressive outreach to doctors, heavier advertising about obesity, tie-ups with clinics, patient incentives and ‍distribution deals with local drug... https://www.scmp.com/news/asia/south-asia/article/3337789/indias-us70-million-obesity-drug-market-bulges-so-does-price-war?utm_source=rss_feed https://www.scmp.com/news/asia/south-asia/article/3337789/indias-us70-million-obesity-drug-market-bulges-so-does-price-war?utm_source=rss_feed Fri, 26 Dec 2025 06:58:14 +0000 Associated Press Associated Press US regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The US Food and Drug Administration’s approval handed drug maker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly’s oral drug, orforglipron, was still under review. Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of... https://www.scmp.com/news/world/united-states-canada/article/3337435/no-need-needles-us-approves-wegovy-pill-weight-loss?utm_source=rss_feed https://www.scmp.com/news/world/united-states-canada/article/3337435/no-need-needles-us-approves-wegovy-pill-weight-loss?utm_source=rss_feed Tue, 23 Dec 2025 04:55:15 +0000 Julie Zhang Julie Zhang Mainland China’s 17 million Alzheimer’s patients can, for the first time, pay less out of pocket for a costly drug touted as “historic” and “the beginning of the end” for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan’s Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural... https://www.scmp.com/business/china-business/article/3336397/chinas-new-drug-insurance-lifeline-patients-or-squeeze-big-pharmaceutical-firms?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3336397/chinas-new-drug-insurance-lifeline-patients-or-squeeze-big-pharmaceutical-firms?utm_source=rss_feed Tue, 16 Dec 2025 23:30:07 +0000 Julie Zhang Julie Zhang Mandi, the Alibaba Health-backed consumer healthcare arm being spun off from mainland drug maker 3SBio, filed for an initial public offering in Hong Kong on Friday, betting that its market-leading minoxidil hair-loss products will attract investors. The deal aims to tap into a red-hot Hong Kong market that has seen US$73 billion in equity capital market activity this year, a 232 per cent surge from the same period in 2024, according to data from the London Stock Exchange Group. The company did... https://www.scmp.com/business/banking-finance/article/3333643/3sbio-spin-mandi-banks-hair-loss-and-weight-loss-drugs-hong-kong-ipo-bid?utm_source=rss_feed https://www.scmp.com/business/banking-finance/article/3333643/3sbio-spin-mandi-banks-hair-loss-and-weight-loss-drugs-hong-kong-ipo-bid?utm_source=rss_feed Fri, 21 Nov 2025 05:37:18 +0000 Bloomberg Bloomberg In 2021, when the world was baking sourdough bread and hoarding toilet paper, Movara was riding a pandemic high. The fitness and weight-loss resort in the red rocks of Ivins, Utah, was packed, sold out for 18 weeks straight. It wasn’t alone. Hilton Head Health, another such resort in South Carolina, similarly had a six- to eight-week wait-list. So did Skyterra Wellness Retreat in Pisgah Forest, North Carolina. The dog days of lockdowns, it turns out, were a boom time for many destination spas in... https://www.scmp.com/magazines/style/beauty/wellness/article/3327605/how-ozempic-and-glp-1-meds-are-reshaping-wellness-resort-offerings?utm_source=rss_feed https://www.scmp.com/magazines/style/beauty/wellness/article/3327605/how-ozempic-and-glp-1-meds-are-reshaping-wellness-resort-offerings?utm_source=rss_feed Sat, 04 Oct 2025 06:00:21 +0000 dpa dpa A new type of weight-loss jab can help people keep weight off by tackling obesity’s underlying causes, researchers say. The drug, called RES-010, is designed to block an RNA molecule called miR-22 – which experts have described as a “master controller” of many processes involved in obesity. These include how the body breaks down and uses fats; the production and activity of mitochondria, the tiny structures that provide cells with energy; and changes in how body fat is organised and how it... https://www.scmp.com/lifestyle/health-wellness/article/3326678/new-weight-loss-jab-could-help-keep-obesity-bay-blocking-its-master-controller?utm_source=rss_feed https://www.scmp.com/lifestyle/health-wellness/article/3326678/new-weight-loss-jab-could-help-keep-obesity-bay-blocking-its-master-controller?utm_source=rss_feed Thu, 25 Sep 2025 04:15:08 +0000 Zhang Tong,Shi Huang,Xinmei Shen Zhang Tong,Shi Huang,Xinmei Shen China has joined the United States in a race to develop technology that could help transform the lives of millions who suffer from debilitating brain injuries or neurodegenerative diseases. In Shanghai this year, a quadruple amputee played a video game through a brain implant that channels his thoughts. Elsewhere, researchers from Tianjin and Beijing inserted implants in 10 volunteers that allowed two-way communication so the brain and machine could learn from each other. Brain-computer... https://www.scmp.com/plus/article/3319931/china-makes-strides-brain-computer-interface-tech-race?utm_source=rss_feed https://www.scmp.com/plus/article/3319931/china-makes-strides-brain-computer-interface-tech-race?utm_source=rss_feed Tue, 29 Jul 2025 07:00:08 +0000